Polyrizon Ltd. and Clearmind Medicine Inc. entered into a development agreement on February 6, 2026 to create an intranasal formulation of Clearmind’s neuroplastogen candidate, 5‑methoxy‑2‑aminoindane (MEAI). The partnership will use Polyrizon’s Capture‑and‑Contain hydrogel platform to deliver MEAI directly to the central nervous system via the nasal route, a non‑invasive method that bypasses first‑pass metabolism and may accelerate clinical development.
MEAI is a non‑hallucinogenic neuroplastogen that Clearmind has advanced to Phase II studies for alcohol use disorder in 2026. The candidate has shown preclinical efficacy in reducing alcohol consumption and cocaine use, and the intranasal formulation is expected to improve bioavailability and patient compliance compared with oral dosing.
Polyrizon’s Capture‑and‑Contain hydrogel platform has previously been applied to allergy and viral‑protection products. By partnering with Clearmind, Polyrizon expands its technology into the addiction and CNS therapeutics market, opening potential revenue streams through licensing or co‑development agreements. The collaboration also validates the platform’s versatility beyond its original indications.
Polyrizon’s market capitalization is approximately $13.06 million and the company is debt‑free, while Clearmind’s market cap is about $2.02 million. Clearmind holds more cash than debt, has reported zero revenue in recent fiscal years, and continues to incur losses, but its convertible note financing provides additional liquidity. The financial context underscores the strategic nature of the partnership for both companies.
Following the announcement, Clearmind’s stock fell 5.19% as investors weighed valuation concerns, whereas Polyrizon’s shares rose 3% reflecting optimism about the new therapeutic area. The mixed market reaction highlights differing investor expectations for the two companies.
Tomer Izraeli, CEO of Polyrizon, said the collaboration “strengthens our position in the CNS space and could unlock new licensing opportunities.” Dr. Adi Zuloff‑Shani, CEO of Clearmind, added that the partnership “leverages Polyrizon’s advanced hydrogel platform to enhance MEAI’s delivery and therapeutic potential.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.